Alcoholism in Britain? There’s a Pill for That

pill

Everything’s coming up binge drinkers!

Britain’s National Institute for Health and Care Excellence (NICE) has approved the use of Nalmefene, a drug that curbs alcohol dependence. NICE serves the English and Welsh National Health Services (NHS) which allows both nations to join Scotland in prescribing the drug.

The Scottish Medicines Consortium (SMC) approved Nalmefene last year to combat the country’s considerably higher rate of alcohol-related deaths, but all three nations require counseling along with the pill.

Got your acronyms down?

NICE expects 35,000 people to receive the Chantix of alcohol dependency in the first year, but only 53 people in Scotland were prescribed the drug since it hit the market.

Chalk it up to denial?

Since a recent study showed that most Americans who think they might be alcoholics are just excessive drinkers, the target demographic for Nalmefene, the drug may soon be Food and Drug Administration (FDA–acronym game strong) approved for more than opioid dependence.

Whether or not this use of the drug crosses the pond, it’s an interesting, albeit pricey, way to deal with a growing problem.

Pop Quiz: Still remember those acronyms?

H/T: The Guardian

 

More content

Lifestyle
Liquid Death Is Giving Away A House With Soda Running Through The Faucets
If you know Liquid Death, then you know it’s no stranger to over-the-top marketing campaigns. For its latest, the beverage-maker has partnered with home building…
,
LifestyleProducts
Protein Packed Doritos Will Hit Shelves Soon
Doritos is an unexpected entrant into the protein group chat. The brand just announced Doritos Protein, a new tortilla-style chip hitting shelves next month with…
,
CultureLifestyle
Amazon Is Shutting Down Its Grocery Stores—And Doubling Down On Delivery And Whole Foods
Amazon is pulling the plug on its Amazon Go and Amazon Fresh physical stores, marking a quiet but telling shift in how the company wants…
,
Burger
We Deliver!

Enter your email address below and we'll deliver our top stories straight to your inbox